

CURRICULUM VITAE



PERSONAL DATA

Name: Chiara Zecca
Nationality: Italian
Current title: PD Dr. med.
Current position: Consultant in Neurology, Leader Senior Physician
Neurology Department, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano
Working address: Multiple Sclerosi Center, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Via Tesserete 46, CH 6903 Lugano, Switzerland
Phone: +41 91 811 6604, E-mail address: chiara.zecca@eoc.ch
Researcher ID: orcid.org/0000-0002-9990-3431

EDUCATION AND TRAINING

December 2018 Didactic course "Teach the teacher", Università della Svizzera italiana
September 2018 Libero Docente, Università della Svizzera italiana
2016-2018 Part-time fellowship in neuroimmunology, Istituto C. Besta, Milano (Dr R. Mantegazza, Dr S. Rossi)
2015 Didactic course "Teach the teacher", Royal College of Physicians, UK.
2014 GCP for investigators and sponsors
2014 Course "Instruments of fund raising of non-profit organisations" (Gli strumenti del fundraising delle aziende non profit), School of Management, Università Bocconi, Milano.
2009, 2012, 2014: 13th, 16th and 17th advanced courses "Magnetic resonance techniques in multiple sclerosis", Neuroimaging research Unit, Università Vita e Salute, Milano.
2010 GCP for Investigators and Sub-investigators certificate
2006 Neurology Certification
Università degli Studi di Milano
Thesis "Caratterizzazione morfologica del modello murino della distrofia facio-scapolo-omeroale"
Mark 70/70 with honours
2006 Advanced theoretical and practical course on "eco colour carotideal and vertebral Doppler" (Corso teorico pratico avanzato di eco color Doppler carotideo e vertebrale), Società Italiana di Diagnostica Vascolare
2006 Course "Communication and counseling of a neurological patient and the family" (la comunicazione ed il counselling con il paziente neurologico e la sua famiglia)
2001-2006 Specialisation to Neurologist, Università degli Studi di Milano
2001 Licence to practice as physician, Università degli Studi di Milano
2001 Medical Degree:
Università degli Studi di Milano
Thesis "Il deficit di disferlina nelle distrofie cingolari e distali"
Mark 110/110 with honours
1995-2001 Studies of medicine, Università degli Studi di Milano
1995 High School Degree:
Liceo Scientifico E. Vittorini, Milano
Mark 60/60

POSITIONS/EMPLOYMENTS

From 2018 Head of the Headache Center, Neurology department, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, CH (Prof. A. Kälin, Dr. C. Städler, Prof Dr. C. Gobbi)
From 2016 Consultant and Leader Senior Physician in Neurology, Deputy-Head of the Multiple Sclerosis Center, Neurology department, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, CH (Prof. A. Kälin, Dr. C. Städler, PD Dr. C. Gobbi)
clinical activities: general neurology, neuroimmunology (multiple sclerosis),
2010-2015 Senior Physician, Neurology department, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, CH (Prof. CL Bassetti, Dr. C. Städler)
clinical activities: general neurology, neuroimmunology (multiple sclerosis)
2007-2009 Resident, Neurology department, Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, CH (Dr. C Tosi, Prof. CL Bassetti)
clinical activities: general neurology, neuroimmunology (multiple sclerosis)

1999-2006 Resident, Neurology department, Ospedale Policlinico Milano (Prof. G Scarlato, Prof. N Bresolin)
clinical activities: general neurology, neuromuscular disorders

RESEARCH ACTIVITY

Academic research

1999-2006 Research activities in the field of **neuromuscular disorders**

Main topic: Development of a mouse model of facio-scapulo-muscular dystrophy

Clinical research

Since 2007: in the field of **multiple sclerosis**. Sponsor and Co-investigator of investigator initiated clinical studies and research projects and Principal investigator and Co-investigator of industry sponsored clinical trials since 2008.

Since 2018 Principal investigator in industry sponsored clinical trials and of research projects with patients with headache

REVIEWER FOR SCIENTIFIC JOURNALS

CML – Multiple Sclerosis, CNS Drugs, Dermatology review, European Journal of Neurology, Expert Review of Neurotherapeutics, Journal of the Neurological Sciences, Multiple Sclerosis Journal, New England Journal of Medicine, Patient Preference and Adherence, Therapeutics and Clinical Risk Management

MEMBERSHIPS

Since 2018 President of the Scientific Advisory Board (SAB) of the Swiss MS-Society

Since 2016 Committee of the Scientific Advisory Board (SAB) of the Swiss MS-Society

2016-2018 ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) Council Member

PUBLICATIONS

17 as first or last author in peer reviewed journals

11 as co-author in peer reviewed journals

13 case reports and reviews in peer reviewed journals

>85 other publications (abstracts, conference communications, posters, articles)

Selection

Zecca C, Pavelek Z, Prikrylova K, Ghielmetti M, Beeler A, Gobbi C. Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: the SFERA Study. Multiple Sclerosis and related Disorders 2019 May 2019;30C:104-109. doi.org/10.1016/j.msard.2019.02.010. IF 3.199.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, **Zecca C**, Gobbi C, Kappos L, Derfuss T Association of Rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis patients With Secondary Progressive Multiple Sclerosis. JAMA Neurol. 2019 Jan 7. doi: 10.1001/jamaneurol.2018.4239. [Epub ahead of print/pubmed/30615019. IF 11.5, Ranking 130/193 (Clinical Neurology).

Zecca C, Bellavia G, Brambilla L, Gutierrez LP, Gerardi C, Fiori AM et al.. Atypical post-injection reactions with delayed onset following glatiramer acetate 40 mg: need of titration? CNS Drugs 2018; <https://doi.org/10.1007/s40263-018-0529-1>. IF 4.02, Ranking Q1.

Scotti B, Disanto G, Sacco R, Guigli M, **Zecca C***, Gobbi C* (*equal contribution) Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS ONE 2018; 13(5): e0197415. <https://doi.org/10.1371/journal.pone.0197415>. IF 3.54.

Zecca C, Roth S, Findling O, Perriard G, Bachmann V, Pless M, Baumann A, Kamm C, Lalive P, Czaplinski A. Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE). Eur J Neurol. 2018 May;25(5):762-767. doi: 10.1111/ene.13594. Epub 2018 Mar 6. IF 3.988, Ranking 41/194 (Clinical Neurology), 66/259 (Neurosciences).

Zecca C, Disanto G, Mühl S, Gobbi C. Subjective patient-reported versus objective adherence to subcutaneous interferon β -1a in multiple sclerosis using RebiSmart®: the CORE study. BMC Neurol. 2017 Sep 4;17(1):171. doi: 10.1186/s12883-017-0952-9. <http://rdcu.be/vz7x>. IF 2.006, Ranking Q2 (Clinical Neurology).

Zecca C, Antozzi CG, Torri Clerici V, Ferrazzini M, RE, Rossi S, Gobbi C. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation. Acta Neurologica Scandinavica 2017 doi 10.1111/ane.12882. . IF 3.087, Ranking 68/194 (Clinical Neurology).